The feasibility of HIV vaccine efficacy trials among Russian injection drug users.
IDU exposure remains a primary driver of the Russian HIV epidemic, and recent incidence data provide little evidence that this epidemic is slowing. While there are multiple important challenges that need to be further explored before starting vaccine trials, most importantly access to evidence-based drug treatment services for trial participants, the current context of high HIV incidence and low genetic diversity of HIV strains, suggests the need for intensified prevention strategies and supports the feasibility of mounting efficacy trials of HIV vaccines among IDUs in the Russian Federation.
Beyrer
Chris
C
Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, MD 21205, USA. cbeyrer@jhsph.edu
Baral
Stefan
S
Shaboltas
Alla
A
Dukhovlinova
Elena
E
Masharsky
Alexey
A
Verevochkin
Sergey
S
Latkin
Carl
C
Heimer
Robert
R
Hoffman
Irving
I
Kozlov
Andrei
A
D016915:AIDS Vaccines / Q000276:immunology*; D006678:HIV / Q000145:classification / Q000235:genetics; D015658:HIV Infections / Q000453:epidemiology* / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D006801:Humans; D012426:Russia / Q000453:epidemiology; D015819:Substance Abuse, Intravenous
D016915:AIDS Vaccines
N Engl J Med. 2004 Jul 8;351(2):117-20
15247350
AIDS. 1999 May 7;13(7):741-9
10357372
AIDS Res Hum Retroviruses. 2007 Feb;23(2):183-92
17331025
Addiction. 2006 Feb;101(2):252-66
16445554
AIDS. 2006 Apr 4;20(6):901-6
16549975
Annu Rev Immunol. 2006;24:227-55
16551249
J Subst Abuse Treat. 2004 Jun;26(4):285-94
15182893
AIDS Res Hum Retroviruses. 2006 Nov;22(11):1074-80
17147492
AIDS. 2007 Feb 19;21(4):403-8
17301558
AIDS. 2004 Nov 19;18(17):2295-303
15577542
AIDS Res Hum Retroviruses. 1999 Nov 20;15(17):1577-83
10580409
AIDS Res Hum Retroviruses. 2003 Oct;19(10):933-9
14601597
J Acquir Immune Defic Syndr. 2006 Apr 15;41(5):657-63
16652041